エピジェネティクス市場規模、シェア、動向、2031年までの世界予測

Epigenetics Market - Global Forecast to 2031

エピジェネティクス市場 - 製品（キット［抗体・試薬］、酵素）、サービス（シングルセル・エピゲノミクス、マルチオミクス）、手法（DNAメチル化、ヒストン修飾）、技術（NGS、PCR、MS）、用途（腫瘍学、免疫学、心血管疾患） - 2031年までの世界市場予測

Epigenetics Market by Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031

出版	MarketsandMarkets
出版年月	2026年06月
ページ数	555
図表数	781
価格	記載以外のライセンスについてはお問合せください
シングルユーザ	USD 4,950
種別	英文調査報告書
商品番号	SMR-23784

エピジェネティクス市場は、2026年の22億2,000万米ドルから2031年には39億2,000万米ドルに達し、予測期間中の年平均成長率（CAGR）は12.0%に達するとMarketsandMarketsでは予測しています。

腫瘍学研究、プレシジョン・メディシン（精密医療）、創薬、バイオマーカー検証、トランスレーショナル研究におけるエピジェネティック解析の利用拡大を背景に、同市場は予測期間を通じて堅調に成長すると見込まれています。次世代シーケンシング、PCR・qPCR、質量分析、超音波処理（ソニケーション）を用いたクロマチン調製、メチル化アレイなどの技術により、DNAメチル化、ヒストン修飾、クロマチンアクセシビリティ、ノンコーディングRNA、クロマチンリモデリングの解析が可能になっています。これらのツールは、がん診断、治療標的の特定、疾患分類、治療反応のモニタリング、発生生物学、免疫学、神経科学、代謝疾患研究など、幅広い分野での応用を支えています。リキッドバイオプシーに基づくメチル化バイオマーカー、シングルセル・エピゲノミクス、マルチオミクス統合、AIを活用したデータ解釈の利用拡大は、製薬、バイオテクノロジー、学術機関、臨床現場、CRO（医薬品開発受託機関）といった各分野での導入をさらに加速させています。また、標準化されたキット、高品質な抗体、シーケンシング用試薬、酵素、自動サンプル調製ソリューション、バイオインフォマティクス・プラットフォームへの需要は、ワークフローの再現性やデータの信頼性向上に寄与しています。一方で、シーケンシングや解析にかかる高コスト、複雑なデータ解釈、抗体性能のばらつき、そして臨床現場での広範な利用に向けたエピジェネティック・ワークフローの標準化の難しさといった課題が、依然として市場成長の障壁となっています。

調査範囲

本調査レポートでは、エピジェネティクス市場を以下の区分で分析しています：製品・サービス（製品、サービス）、製品［キット・試薬（抗体、単離・抽出キット／試薬、ChIP-seqキット／試薬、重亜硫酸塩変換キット／試薬、全ゲノム増幅キット／試薬、CUT&RUN／CUT&TAGキット／試薬、5-hmC／5-mC解析キット／試薬、ヒストン、その他キット・試薬）、酵素（DNAポリメラーゼ、DNAリガーゼ、Tn5トランスポザーゼ、変換酵素［TETおよびAPOBEC］、タンパク質修飾酵素、その他酵素）、機器・アクセサリー］、サービス（DNAメチル化プロファイリング、クロマチンプロファイリング、クロマチンアクセシビリティ・プロファイリング、シングルセル・エピゲノミクス、マルチオミクス、その他サービス）、技術（次世代シーケンシング、PCR／qPCR、質量分析、超音波処理、その他技術）、手法（DNAメチル化、ヒストン修飾、その他手法）、用途（腫瘍学、代謝性疾患、免疫学、発生生物学、心血管疾患、集団スクリーニング、その他用途）、エンドユーザー別製品市場（学術・研究機関、製薬・バイオテクノロジー企業、病院・クリニック、受託研究機関［CRO］）、エンドユーザー別サービス市場（製薬・バイオテクノロジー企業、学術・研究機関、病院・クリニック、受託研究機関［CRO］）、および地域（北米、欧州、アジア太平洋、中南米、中東・アフリカ）。

本レポートは、エピジェネティクス市場の成長に影響を与える主要因（促進要因、抑制要因、課題、機会）に関する詳細情報を提供します。主要な業界プレーヤーについて包括的な分析を行い、事業概要、製品ポートフォリオ、主要戦略、新製品投入、買収、およびエピジェネティクス市場に関連する最近の動向についての知見を提供します。また、エピジェネティクス業界のエコシステムにおける新興スタートアップ企業の競争分析も含まれています。

本レポートを購入する主なメリット

本レポートは、市場全体および各セグメントの収益予測を提供することで、市場のリーダー企業や新規参入企業を支援します。また、ステークホルダーが競争環境を深く理解し、効果的な事業のポジショニングや適切な市場参入戦略（Go-to-Market戦略）を策定するための知見を提供します。さらに、市場の動向を把握し、主要な市場促進要因、抑制要因、機会、課題に関する情報を提供します。

本レポートでは、以下の点に関する知見を提供します

市場の成長に影響を与える要因の分析：主要な促進要因（シーケンシングのコストと所要時間の低下、集団スクリーニング・プログラムへの注目の高まり、エピジェネティクス研究における技術的進歩、エピジェネティック薬およびエピジェネティクスに基づく治療法への需要拡大）、阻害要因（毒性学におけるエピゲノムデータの応用の限定性、データプライバシーやセキュリティに関する懸念）、機会（エピジェネティクスの新たな応用、マルチオミクス統合）、および課題（抗体の品質に関する懸念、エピジェネティック編集に伴う課題）

製品開発・イノベーション：エピジェネティクス市場における新製品や技術革新に関する詳細な情報
市場展開：有望な市場に関する包括的な情報および各地域における市場分析
市場の多角化：エピジェネティクス市場における新製品、未開拓地域、最近の動向、投資活動に関する網羅的な情報
競合状況の評価：Thermo Fisher Scientific Inc.（米国）、Merck KGaA（ドイツ）、Illumina, Inc.（米国）、PacBio（米国）、Danaher Corporation（米国）、Bio-Rad Laboratories, Inc.（米国）、Active Motif, Inc.（米国）、New England Biolabs（米国）、QIAGEN（オランダ）、Zymo Research Corporation（米国）、Revvity（米国）などの主要企業について、市場シェア、成長戦略、製品・サービスを詳細に評価

Report Description

The epigenetics market is expected to reach USD 3.92 billion in 2031 from USD 2.22 billion in 2026, at a CAGR of 12.0% during the forecast period. The market is expected to grow steadily during the forecast period, driven by increasing use of epigenetic analysis in oncology research, precision medicine, drug discovery, biomarker validation, and translational studies. Technologies such as next-generation sequencing, PCR & qPCR, mass spectrometry, sonication-based chromatin preparation, and methylation arrays enable the analysis of DNA methylation, histone modifications, chromatin accessibility, non-coding RNAs, and chromatin remodeling. These tools support applications across cancer diagnostics, therapeutic target identification, disease classification, treatment response monitoring, developmental biology, immunology, neuroscience, and metabolic disease research. The growing use of liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration, and AI-enabled data interpretation is further strengthening adoption across pharmaceutical, biotechnology, academic, clinical, and CRO settings. In addition, demand for standardized kits, high-quality antibodies, sequencing reagents, enzymes, automated sample preparation solutions, and bioinformatics platforms is improving workflow reproducibility and data reliability. However, market growth continues to be challenged by high sequencing and analysis costs, complex data interpretation, variability in antibody performance, and difficulties in standardizing epigenetic workflows for broader clinical use.

エピジェネティクス市場規模、シェア、動向、2031年までの世界予測 - by method

Epigenetics Market – Global Forecast to 2031 – by method

“DNA methylation segment is expected to grow at the highest CAGR during the forecast period”

The DNA methylation segment is projected to grow at the highest CAGR in the epigenetics market due to its increasing use in cancer detection, biomarker discovery, disease classification, and treatment response monitoring. DNA methylation assays are widely used to study promoter methylation, gene silencing, epigenetic aging, tumor profiling, and liquid biopsy-based diagnostics. The growing adoption of bisulfite sequencing, methylation-specific PCR, methylation arrays, and NGS-based methylation profiling is strengthening demand across pharmaceutical research, clinical laboratories, and translational studies.

“Next-generation sequencing segment holds the largest share of the market”

The next-generation sequencing segment accounts for the largest share of the epigenetics market, driven by its ability to generate high-throughput, genome-wide insights into epigenetic regulation. NGS is widely used in DNA methylation profiling, ChIP-seq, ATAC-seq, chromatin accessibility studies, and single-cell epigenomics. Its strong adoption across oncology research, biomarker discovery, drug development, and precision medicine supports its leading position. The increasing need for deeper epigenomic coverage, scalable analysis, and integration with multi-omics workflows continues to strengthen demand for NGS-based epigenetics solutions.

“The US is expected to grow at the highest CAGR during the forecast period”

The US is expected to grow at the highest CAGR in the epigenetics market due to its strong presence of sequencing, molecular biology, diagnostics, and bioinformatics companies, advanced research infrastructure, and high adoption of epigenomic technologies across research and clinical settings. Rising use of epigenetics in oncology, precision medicine, drug discovery, liquid biopsy development, and biomarker validation is driving market growth. Technologies such as next-generation sequencing, PCR & qPCR, methylation arrays, ChIP-seq, ATAC-seq, and single-cell epigenomics are widely used across pharmaceutical companies, biotechnology firms, academic institutes, CROs, and clinical laboratories.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side – 70% and Demand Side– 30%
By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%

エピジェネティクス市場規模、シェア、動向、2031年までの世界予測 - 対象企業

Epigenetics Market – Global Forecast to 2031 – by ecosystem

Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), Revvity (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), EpigenTek Group Inc. (US), EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), BPS Bioscience, Inc. (US), Abnova Corporation (Taiwan), Creative Diagnostics (US), Biomodal (UK), 10x Genomics (US), and Novogene Co., Ltd. (China) are some of the key companies offering epigenetics products and services.

Research Coverage

This research report categorizes the epigenetics market by offering (products and services), product [kits & reagents {antibodies, isolation/extraction kits & reagents, ChIP-sequencing kits & reagents, bisulfite conversion kits & reagents, whole-genome amplification kits & reagents, CUT&RUN/CUT&TAG kits & reagents, 5-hmC & 5-mC analysis kits & reagents, histones, and other kits & reagents}, enzymes {DNA polymerases, DNA ligases, Tn5 transposase, conversion enzymes [TET & APOBEC], protein-modifying enzymes, and other enzymes}, and instruments & accessories], service (DNA methylation profiling services, chromatin profiling services, chromatin accessibility profiling services, single-cell epigenomics services, multi-omics services, and other services), technology (next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies), method (DNA methylation, histone modifications, and other methods), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, population screening, and other applications), products market by end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), services market by end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, and contract research organizations), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the epigenetics market. This report also includes a competitive analysis of emerging startups in the epigenetics industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market’s pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (declining sequencing costs and time, growing emphasis on population screening programs, technological advancements in epigenetics research, rising demand for epigenetic drugs and epigenetic-based therapeutics), restraints (limited applications of epigenomic data in toxicology, data privacy concerns and security issues), opportunities (emerging applications of epigenetics, integration of multi-omics), and challenges (concerns regarding quality of antibodies, challenges associated with epigenetic editing) influencing the market growth
Product Development/Innovation: Detailed insights into newly launched products and innovations in the epigenetics market
Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), and Revvity (US), among others, for the epigenetics market

1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.3 MARKET SCOPE 46
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 47
1.3.2 INCLUSIONS & EXCLUSIONS 48
1.3.3 YEARS CONSIDERED 49
1.3.4 CURRENCY CONSIDERED 49
1.4 STAKEHOLDERS 50
1.5 SUMMARY OF CHANGES 50
2 EXECUTIVE SUMMARY 51
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 51
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 53
2.3 DISRUPTIVE TRENDS IN EPIGENETICS MARKET 54
2.4 HIGH-GROWTH SEGMENTS 55
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 56
3 PREMIUM INSIGHTS 57
3.1 EPIGENETICS MARKET OVERVIEW 57
3.2 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD AND COUNTRY 58
3.3 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
3.4 EPIGENETICS MARKET SHARE, BY OFFERING, 2026 VS. 2031 59
4 MARKET OVERVIEW 60
4.1 INTRODUCTION 60
4.2 MARKET DYNAMICS 60
4.2.1 DRIVERS 61
4.2.1.1 Declining sequencing costs and time 61
4.2.1.2 Growing emphasis on population-scale screening initiatives 62
4.2.1.3 Technological advancements in epigenetics research 62
4.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics 62
4.2.2 RESTRAINTS 63
4.2.2.1 Limited applications of epigenomic data in toxicology 63
4.2.2.2 Data privacy concerns and security issues 63
4.2.3 OPPORTUNITIES 64
4.2.3.1 Emerging applications of epigenetics 64
4.2.3.2 Integration of multi-omics 64
4.2.4 CHALLENGES 64
4.2.4.1 Concerns regarding quality of antibodies 64
4.2.4.2 Challenges associated with epigenetic editing 65
4.3 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65
4.4 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 66
5 INDUSTRY TRENDS 67
5.1 PORTER’S FIVE FORCES ANALYSIS 67
5.1.1 BARGAINING POWER OF SUPPLIERS 68
5.1.2 BARGAINING POWER OF BUYERS 68
5.1.3 THREAT OF NEW ENTRANTS 69
5.1.4 THREAT OF SUBSTITUTES 69
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.2 MACROECONOMIC OUTLOOK 69
5.2.1 INTRODUCTION 69
5.2.2 GDP TRENDS AND FORECAST 70
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 70
5.2.4 TRENDS IN GLOBAL BIOTECH & PHARMA INDUSTRY 71
5.3 VALUE CHAIN ANALYSIS 71
5.4 ECOSYSTEM ANALYSIS 73
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 74
5.5 PRICING ANALYSIS 76
5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2023–2025 76
5.5.1.1 Average selling price trend, by instrument, 2023–2025 76
5.5.1.2 Average selling price trend, by kits & reagents, 2023–2025 77
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 77
5.6 TRADE ANALYSIS 78
5.6.1 IMPORT SCENARIO (HS CODE 9027.50) 79
5.6.2 EXPORT SCENARIO (HS CODE 9027.50) 80
5.6.3 IMPORT SCENARIO (HS CODE 3822.00) 81
5.6.4 EXPORT SCENARIO (HS CODE 3822.00) 82
5.7 KEY CONFERENCES & EVENTS, 2026–2027 83
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84
5.9 INVESTMENT & FUNDING SCENARIO 85
5.10 CASE STUDY ANALYSIS 86
5.10.1 CFDNA METHYLOME–FRAGMENTOME PROFILING STRENGTHENS MULTICANCER DETECTION 86
5.10.2 5-BASE NGS WORKFLOW ENABLES INTEGRATED METHYLATION AND
VARIANT PROFILING 86
5.10.3 LONG-READ SEQUENCING SCALES NATIVE EPIGENOME ANALYSIS
IN AGING RESEARCH 87
5.11 IMPACT OF 2025 US TARIFF ON EPIGENETICS MARKET 87
5.11.1 INTRODUCTION 87
5.11.2 KEY TARIFF RATES 87
5.11.3 PRICE IMPACT ANALYSIS 88
5.11.4 IMPACT ON COUNTRIES/REGIONS 89
5.11.4.1 US 89
5.11.4.2 Europe 89
5.11.4.3 Asia Pacific 90
5.11.5 IMPACT ON END-USE INDUSTRIES 90
5.11.5.1 Pharmaceutical and biotechnology companies 90
5.11.5.2 Contract research organizations 90
5.11.5.3 Academic and research institutes 91
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 92
6.1 INTRODUCTION 92
6.1.1 KEY TECHNOLOGIES 92
6.1.1.1 DNA methylation conversion technologies 92
6.1.1.2 Chromatin immunoprecipitation/ChIP 92
6.1.1.3 ATAC-based chromatin accessibility profiling 93
6.1.2 COMPLEMENTARY TECHNOLOGIES 93
6.1.2.1 Single-cell partitioning and epigenomic barcoding 93
6.1.2.2 AI/ML-based epigenomic interpretation 93
6.1.3 ADJACENT TECHNOLOGIES 94
6.1.3.1 CRISPR-based epigenome modulation 94
6.1.3.2 Spatial epigenomics 94
6.2 TECHNOLOGY ROADMAP 95
6.3 PATENT ANALYSIS 95
6.3.1 METHODOLOGY 95
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 95
6.3.3 LIST OF KEY PATENTS 97
6.4 FUTURE APPLICATIONS 97
6.5 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET 98
6.5.1 TOP USE CASES AND MARKET POTENTIAL 99
6.5.2 BEST PRACTICES IN AI-ENABLED EPIGENETICS WORKFLOWS 100
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET 100
6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS 101
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES 101
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 103
7.1 REGIONAL REGULATIONS AND COMPLIANCE 103
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
7.1.2 INDUSTRY STANDARDS 107
7.1.2.1 North America 107
7.1.2.2 Europe 107
7.1.2.3 Asia Pacific 108
7.1.2.4 Rest of the World 108
7.2 SUSTAINABILITY INITIATIVES 108
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 109
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS 109
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113
8.1 DECISION-MAKING PROCESS 113
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 113
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113
8.2.2 KEY BUYING CRITERIA 114
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 115
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 116
9 EPIGENETICS MARKET, BY OFFERING 117
9.1 INTRODUCTION 118
9.2 PRODUCTS 118
9.2.1 RISING ADOPTION OF WORKFLOW-READY EPIGENETICS
PRODUCTS TO PROPEL MARKET 118
9.3 SERVICES 121
9.3.1 RISING OUTSOURCING OF COMPLEX EPIGENOMIC WORKFLOWS
TO DRIVE MARKET 121
10 EPIGENETICS MARKET, BY PRODUCT 125
10.1 INTRODUCTION 126
10.2 KITS & REAGENTS 127
10.2.1 ANTIBODIES 131
10.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market 131
10.2.2 ISOLATION/EXTRACTION KITS & REAGENTS 134
10.2.2.1 Rising need for high-quality, automation-ready sample preparation to propel market 134
10.2.3 CHIP-SEQUENCING KITS & REAGENTS 138
10.2.3.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market 138
10.2.4 BISULFITE CONVERSION KITS & REAGENTS 141
10.2.4.1 Effective outcomes associated with bisulfite conversion to sustain growth 141
10.2.5 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS 145
10.2.5.1 Rising use of low-input and single-cell epigenomic workflows to stimulate growth 145
10.2.6 CUT&RUN/CUT&TAG KITS & REAGENTS 148
10.2.6.1 Rising adoption of low-input chromatin profiling workflows to stimulate growth 148
10.2.7 5-HMC & 5-MC ANALYSIS KITS & REAGENTS 152
10.2.7.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth 152
10.2.8 HISTONES 155
10.2.8.1 Rising importance of chromatin-associated proteins and histones in epigenetic research to propel growth 155
10.2.9 OTHER KITS & REAGENTS 159
10.3 ENZYMES 162
10.3.1 DNA POLYMERASES 165
10.3.1.1 Rising need for uracil-tolerant, low-bias DNA amplification to facilitate growth 165
10.3.2 DNA LIGASES 169
10.3.2.1 Rising need for efficient adapter ligation in low-input epigenomic library preparation to spur growth 169
10.3.3 TN5 TRANSPOSASE 172
10.3.3.1 Rising adoption of tagmentation-based chromatin profiling to facilitate growth 172
10.3.4 CONVERSION ENZYMES 176
10.3.4.1 Rising shift toward enzymatic DNA conversion for low-damage methylome profiling to spur growth 176
10.3.5 PROTEIN-MODIFYING ENZYMES 179
10.3.5.1 Rising focus on histone post-translational modification analysis to spur growth 179
10.3.6 OTHER ENZYMES 183
10.4 INSTRUMENTS & ACCESSORIES 186
10.4.1 RISING ADOPTION OF HIGH-THROUGHPUT, AUTOMATED, AND LONG-READ EPIGENOMIC PLATFORMS TO EXPEDITE GROWTH 186
11 EPIGENETICS MARKET, BY SERVICE 190
11.1 INTRODUCTION 191
11.2 DNA METHYLATION PROFILING SERVICES 191
11.2.1 OUTSOURCING OF COMPLEX METHYLATION WORKFLOWS AND ONCOLOGY BIOMARKER RESEARCH TO DRIVE MARKET 191
11.3 CHROMATIN PROFILING SERVICES 195
11.3.1 RISING OUTSOURCING OF LOW-INPUT AND MULTI-OMIC CHROMATIN MAPPING WORKFLOWS TO DRIVE MARKET 195
11.4 CHROMATIN ACCESSIBILITY PROFILING SERVICES 198
11.4.1 RISING USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET 198
11.5 SINGLE-CELL EPIGENOMICS SERVICES 202
11.5.1 RISING NEED FOR CELL-LEVEL REGULATORY INSIGHTS TO AID GROWTH 202
11.6 MULTI-OMICS SERVICES 205
11.6.1 RISING DEMAND FOR INTEGRATED EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC INTERPRETATION TO SUPPORT GROWTH 205
11.7 OTHER SERVICES 209
12 EPIGENETICS MARKET, BY TECHNOLOGY 213
12.1 INTRODUCTION 214
12.2 NEXT-GENERATION SEQUENCING 214
12.2.1 INCREASING LAUNCHES OF NGS PLATFORMS TO DRIVE GROWTH 214
12.3 PCR & QPCR 218
12.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET 218
12.4 MASS SPECTROMETRY 222
12.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET 222
12.5 SONICATION 225
12.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO DRIVE MARKET 225
12.6 OTHER TECHNOLOGIES 229
13 EPIGENETICS MARKET, BY METHOD 233
13.1 INTRODUCTION 234
13.2 DNA METHYLATION 234
13.2.1 RISING USE OF METHYLATION-BASED BIOMARKERS IN ONCOLOGY, LIQUID BIOPSY, AND PRECISION MEDICINE TO SPUR GROWTH 234
13.3 HISTONE MODIFICATION 238
13.3.1 EXPANDING USE OF HISTONE MODIFICATION PROFILING IN CHROMATIN BIOLOGY, DRUG DISCOVERY, AND MULTI-OMICS RESEARCH TO DRIVE MARKET 238
13.4 OTHER METHODS 242
14 EPIGENETICS MARKET, BY APPLICATION 245
14.1 INTRODUCTION 246
14.2 ONCOLOGY 246
14.2.1 RISING USE OF EPIGENETIC BIOMARKERS AND CHROMATIN-REGULATING DRUG TARGETS TO BOOST MARKET 246
14.3 METABOLIC DISEASES 252
14.3.1 INCREASING USE OF DNA METHYLATION BIOMARKERS TO ADVANCE METABOLIC DISEASE RISK PREDICTION AND THERAPEUTIC RESEARCH 252
14.4 IMMUNOLOGY 255
14.4.1 RISING USE OF EPIGENETIC IMMUNE PROFILING TO DRIVE MARKET 255
14.5 DEVELOPMENTAL BIOLOGY 259
14.5.1 INCREASED USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET 259
14.6 CARDIOVASCULAR DISEASES 262
14.6.1 RISING USE OF DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR RISK PREDICTION AND THERAPEUTIC TARGET DISCOVERY TO AID GROWTH 262
14.7 POPULATION SCREENING 266
14.7.1 INCREASING USE OF DNA METHYLATION BIOMARKERS FOR EXPOSURE-LINKED POPULATION RISK ASSESSMENT TO AID GROWTH 266
14.8 OTHER APPLICATIONS 269
15 EPIGENETIC PRODUCTS MARKET, BY END USER 273
15.1 INTRODUCTION 274
15.2 ACADEMIC & RESEARCH INSTITUTES 274
15.2.1 INCREASED IN-HOUSE ADOPTION OF ADVANCED EPIGENOMICS PRODUCTS ACROSS ACADEMIC DISCOVERY RESEARCH TO FAVOR GROWTH 274
15.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 278
15.3.1 RISING USE OF EPIGENETICS PRODUCTS IN DRUG DISCOVERY
TO PROPEL MARKET 278
15.4 HOSPITALS & CLINICS 281
15.4.1 RISING INTEGRATION OF METHYLATION-BASED MOLECULAR PROFILING IN HOSPITAL ONCOLOGY WORKFLOWS TO PROPEL MARKET 281
15.5 CONTRACT RESEARCH ORGANIZATIONS 285
15.5.1 INCREASING DEMAND FOR STANDARDIZED AND SCALABLE EPIGENOMIC WORKFLOWS TO DRIVE MARKET 285
16 EPIGENETICS SERVICES MARKET, BY END USER 289
16.1 INTRODUCTION 290
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 290
16.2.1 RISING USE OF OUTSOURCED EPIGENETIC BIOMARKER AND TARGET-VALIDATION SERVICES TO ACCELERATE DRUG DEVELOPMENT DECISIONS 290
16.3 ACADEMIC & RESEARCH INSTITUTES 294
16.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH 294
16.4 HOSPITALS & CLINICS 297
16.4.1 RISING USE OF OUTSOURCED METHYLATION PROFILING AND CLASSIFIER-BASED INTERPRETATION TO AID GROWTH 297
17 EPIGENETICS MARKET, BY REGION 301
17.1 INTRODUCTION 302
17.2 NORTH AMERICA 302
17.2.1 US 309
17.2.1.1 Strong pharmaceutical R&D intensity and advanced genomics infrastructure to drive market 309
17.2.2 CANADA 314
17.2.2.1 Presence of advanced clinical genomics infrastructure to support market growth 314
17.3 EUROPE 319
17.3.1 GERMANY 324
17.3.1.1 Established life sciences supply ecosystem to drive market 324
17.3.2 UK 328
17.3.2.1 Growing emphasis on precision medicine to propel market 328
17.3.3 FRANCE 333
17.3.3.1 Strong oncology research ecosystem to support market growth 333
17.3.4 ITALY 338
17.3.4.1 High incidence of cancer to drive market 338
17.3.5 SPAIN 342
17.3.5.1 Well-established network of research centers and universities to propel market 342
17.3.6 REST OF EUROPE 346
17.4 ASIA PACIFIC 351
17.4.1 CHINA 356
17.4.1.1 Advanced methylation detection and sequencing service capacity to accelerate growth 356
17.4.2 JAPAN 360
17.4.2.1 Increasing collaborations between research & academic organizations to favor growth 360
17.4.3 INDIA 365
17.4.3.1 Expanding genomics infrastructure to drive market 365
17.4.4 AUSTRALIA 369
17.4.4.1 Strong genomics infrastructure to propel market 369
17.4.5 SOUTH KOREA 373
17.4.5.1 Methylation profiling and AI-enabled epigenomic analysis to foster growth 373
17.4.6 REST OF ASIA PACIFIC 378
17.5 LATIN AMERICA 383
17.5.1 BRAZIL 387
17.5.1.1 Rising prevalence of chronic diseases to drive market 387
17.5.2 MEXICO 392
17.5.2.1 Growing adoption of cutting-edge technologies to drive market 392
17.5.3 REST OF LATIN AMERICA 396
17.6 MIDDLE EAST 401
17.6.1 GCC COUNTRIES 406
17.6.1.1 Saudi Arabia 410
17.6.1.1.1 Growing healthcare expenditure to propel market 410
17.6.1.2 UAE 415
17.6.1.2.1 National genomics programs and methylation-enabled sequencing to spur growth 415
17.6.1.3 Rest of GCC countries 419
17.6.2 REST OF MIDDLE EAST 424
17.7 AFRICA 429
17.7.1 POPULATION-SPECIFIC BIOMARKER DISCOVERY AND DISEASE-FOCUSED METHYLATION RESEARCH TO AUGMENT GROWTH 429
18 COMPETITIVE LANDSCAPE 435
18.1 INTRODUCTION 435
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–MAY 2026 435
18.3 REVENUE ANALYSIS 437
18.4 MARKET SHARE ANALYSIS, 2025 438
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 440
18.5.1 STARS 441
18.5.2 EMERGING LEADERS 441
18.5.3 PERVASIVE PLAYERS 441
18.5.4 PARTICIPANTS 441
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 443
18.5.5.1 Company footprint 443
18.5.5.2 Region footprint 444
18.5.5.3 Product footprint 445
18.5.5.4 Service footprint 446
18.5.5.5 Method footprint 447
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 448
18.6.1 PROGRESSIVE COMPANIES 448
18.6.2 RESPONSIVE COMPANIES 448
18.6.3 DYNAMIC COMPANIES 448
18.6.4 STARTING BLOCKS 448
18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 450
18.6.5.1 Detailed list of key startups/SMEs 450
18.6.5.2 Competitive benchmarking of key startups/SMEs 451
18.7 COMPANY VALUATION AND FINANCIAL METRICS 452
18.7.1 COMPANY VALUATION 452
18.7.2 FINANCIAL METRICS 452
18.8 BRAND COMPARISON 453
18.9 COMPETITIVE SCENARIO 454
18.9.1 PRODUCT/SERVICE LAUNCHES 454
18.9.2 DEALS 455
19 COMPANY PROFILES 456
19.1 KEY PLAYERS 456
19.1.1 THERMO FISHER SCIENTIFIC INC. 456
19.1.1.1 Business overview 456
19.1.1.2 Products/services offered 457
19.1.1.3 Recent developments 460
19.1.1.3.1 Product launches 460
19.1.1.3.2 Deals 460
19.1.1.4 MnM view 461
19.1.1.4.1 Key strengths 461
19.1.1.4.2 Strategic choices 461
19.1.1.4.3 Weaknesses and competitive threats 461
19.1.2 ILLUMINA, INC. 462
19.1.2.1 Business overview 462
19.1.2.2 Products/Services offered 464
19.1.2.3 Recent developments 466
19.1.2.3.1 Product launches 466
19.1.2.3.2 Deals 467
19.1.2.4 MnM view 467
19.1.2.4.1 Key strengths 467
19.1.2.4.2 Strategic choices 467
19.1.2.4.3 Weaknesses and competitive threats 467
19.1.3 MERCK KGAA 468
19.1.3.1 Business overview 468
19.1.3.2 Products/Services offered 469
19.1.3.3 MnM view 471
19.1.3.3.1 Key strengths 471
19.1.3.3.2 Strategic choices 471
19.1.3.3.3 Weaknesses and competitive threats 471
19.1.4 DANAHER CORPORATION 472
19.1.4.1 Business overview 472
19.1.4.2 Products/Services offered 473
19.1.4.3 Recent developments 475
19.1.4.3.1 Deals 475
19.1.4.4 MnM view 475
19.1.4.4.1 Key strengths 475
19.1.4.4.2 Strategic choices 475
19.1.4.4.3 Weaknesses and competitive threats 475
19.1.5 BIO-RAD LABORATORIES, INC. 476
19.1.5.1 Business overview 476
19.1.5.2 Products/Services offered 477
19.1.5.3 MnM view 481
19.1.5.3.1 Key strengths 481
19.1.5.3.2 Strategic choices 481
19.1.5.3.3 Weaknesses and competitive threats 481
19.1.6 REVVITY 482
19.1.6.1 Business overview 482
19.1.6.2 Products/Services offered 483
19.1.7 PACBIO 485
19.1.7.1 Business overview 485
19.1.7.2 Products/Services offered 486
19.1.7.3 Recent developments 487
19.1.7.3.1 Product launches 487
19.1.7.3.2 Deals 488
19.1.8 ACTIVE MOTIF, INC. 489
19.1.8.1 Business overview 489
19.1.8.2 Products/Services offered 489
19.1.8.3 Recent developments 492
19.1.8.3.1 Deals 492
19.1.9 NEW ENGLAND BIOLABS 493
19.1.9.1 Business overview 493
19.1.9.2 Products/Services offered 493
19.1.9.3 Recent developments 495
19.1.9.3.1 Product launches 495
19.1.9.3.2 Deals 496
19.1.10 QIAGEN 497
19.1.10.1 Business overview 497
19.1.10.2 Products/services offered 498
19.1.10.3 Recent developments 499
19.1.10.3.1 Product launches 499
19.1.11 ZYMO RESEARCH CORPORATION 500
19.1.11.1 Business overview 500
19.1.11.2 Products/Services offered 500
19.1.11.3 Recent developments 503
19.1.11.3.1 Product launches 503
19.1.11.3.2 Deals 503
19.1.12 HOLOGIC DIAGENODE 504
19.1.12.1 Business overview 504
19.1.12.2 Products/services offered 505
19.1.13 F. HOFFMANN-LA ROCHE LTD. 508
19.1.13.1 Business overview 508
19.1.13.2 Products/services offered 509
19.1.14 PROMEGA CORPORATION 511
19.1.14.1 Business overview 511
19.1.14.2 Products/services offered 511
19.1.15 EPIGENTEK GROUP INC. 513
19.1.15.1 Business overview 513
19.1.15.2 Products/Services offered 513
19.1.15.3 Recent developments 517
19.1.15.3.1 Product launches 517
19.2 OTHER PLAYERS 519
19.2.1 EPICYPHER 519
19.2.2 FIOS GENOMICS 520
19.2.3 GENOMESCAN 521
19.2.4 CREATIVE BIOGENE 522
19.2.5 BPS BIOSCIENCE, INC. 523
19.2.6 ABNOVA CORPORATION 524
19.2.7 CREATIVE DIAGNOSTICS 525
19.2.8 BIOMODAL 526
19.2.9 10X GENOMICS 527
19.2.10 NOVOGENE CO., LTD. 528
20 RESEARCH METHODOLOGY 529
20.1 RESEARCH DATA 529
20.1.1 SECONDARY DATA 530
20.1.1.1 Key data from secondary sources 530
20.1.2 PRIMARY DATA 531
20.1.2.1 Key data from primary sources 531
20.1.2.2 Key primary participants 531
20.1.2.3 Breakdown of primary interviews 532
20.1.2.4 Key industry insights 533
20.2 MARKET SIZE ESTIMATION 534
20.2.1 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025 534
20.2.2 SEGMENTAL MARKET SIZE ESTIMATION 537
20.3 MARKET GROWTH RATE PROJECTIONS 538
20.4 DATA TRIANGULATION 540
20.5 FACTOR ANALYSIS 541
20.6 RESEARCH ASSUMPTIONS 541
20.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 542
21 APPENDIX 544
21.1 DISCUSSION GUIDE 544
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 550
21.3 CUSTOMIZATION OPTIONS 552
21.4 RELATED REPORTS 552
21.5 AUTHOR DETAILS 553

LIST OF TABLES

TABLE 1 EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS 48
TABLE 2 EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 61
TABLE 3 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS 67
TABLE 4 EPIGENETICS MARKET: ROLE OF PLAYERS IN ECOSYSTEM 74
TABLE 5 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, 2023–2025 76
TABLE 6 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS,
2023–2025 (USD) 77
TABLE 7 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2023–2025 (USD) 77
TABLE 8 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, BY REGION, 2023–2025 (USD) 78
TABLE 9 IMPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 79
TABLE 10 EXPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 80
TABLE 11 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 81
TABLE 12 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 82
TABLE 13 EPIGENETICS MARKET: LIST OF KEY CONFERENCES & EVENTS,
JANUARY 2026–JUNE 2027 83
TABLE 14 RECIPROCAL TARIFF RATES ADJUSTED BY US 87
TABLE 15 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 89
TABLE 16 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025 95
TABLE 17 LIST OF KEY PATENTS IN EPIGENETICS MARKET, 2023–2025 97
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET 100
TABLE 19 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES 102
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 103
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 105
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 105
TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 106
TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 106
TABLE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE 114
TABLE 27 KEY BUYING CRITERIA, BY END USER 114
TABLE 28 EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 118
TABLE 29 EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 118
TABLE 30 NORTH AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 119
TABLE 31 EUROPE: EPIGENETIC PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 119
TABLE 32 ASIA PACIFIC: EPIGENETIC PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 120
TABLE 33 LATIN AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 120
TABLE 34 MIDDLE EAST: EPIGENETIC PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 121
TABLE 35 GCC COUNTRIES: EPIGENETIC PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 121
TABLE 36 EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 37 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 122
TABLE 38 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 123
TABLE 39 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 123
TABLE 40 LATIN AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 41 MIDDLE EAST: EPIGENETIC SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 124
TABLE 42 GCC COUNTRIES: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 43 EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 126
TABLE 44 EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,
2024–2031 (USD MILLION) 127
TABLE 45 EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION,
2024–2031 (USD MILLION) 128
TABLE 46 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 47 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 48 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 49 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 50 MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION,
2024–2031 (USD MILLION) 130
TABLE 51 GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 52 EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 53 NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,
2024–2031 (USD MILLION) 132
TABLE 54 EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,
2024–2031 (USD MILLION) 132
TABLE 55 ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 56 LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 57 MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 58 GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 59 EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS,
BY REGION, 2024–2031 (USD MILLION) 135
TABLE 60 NORTH AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 61 EUROPE: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 62 ASIA PACIFIC: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 63 LATIN AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 64 MIDDLE EAST: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 65 GCC COUNTRIES: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 66 EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 138
TABLE 67 NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 68 EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 69 ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 70 LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 71 MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 72 GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 73 EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS,
BY REGION, 2024–2031 (USD MILLION) 142
TABLE 74 NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 75 EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 76 ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 77 LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 78 MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 144
TABLE 79 GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 80 EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 81 NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 82 EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 83 ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 84 LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 85 MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 86 GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 87 EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 88 NORTH AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 89 EUROPE: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 90 ASIA PACIFIC: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 91 LATIN AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 92 MIDDLE EAST: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 151
TABLE 93 GCC COUNTRIES: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 94 EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 152
TABLE 95 NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 96 EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 97 ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 98 LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 99 MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 154
TABLE 100 GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 101 EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION) 156
TABLE 102 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 103 EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 104 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 105 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 106 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 107 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 108 EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION,
2024–2031 (USD MILLION) 159
TABLE 109 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 110 EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 111 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 112 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 113 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS,
BY REGION, 2024–2031 (USD MILLION) 161
TABLE 114 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 115 EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2024–2031 (USD MILLION) 162
TABLE 116 EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION) 162
TABLE 117 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 118 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 119 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 120 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 121 MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION,
2024–2031 (USD MILLION) 164
TABLE 122 GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,
2024–2031 (USD MILLION) 165
TABLE 123 EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION,
2024–2031 (USD MILLION) 166
TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 125 EUROPE: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 127 LATIN AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 128 MIDDLE EAST: EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION) 168
TABLE 129 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 130 EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION) 169
TABLE 131 NORTH AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY,
2024–2031 (USD MILLION) 170
TABLE 132 EUROPE: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY,
2024–2031 (USD MILLION) 170
TABLE 133 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 134 LATIN AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 135 MIDDLE EAST: EPIGENETICS MARKET FOR DNA LIGASES, BY REGION,
2024–2031 (USD MILLION) 171
TABLE 136 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY,
2024–2031 (USD MILLION) 172
TABLE 137 EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION,
2024–2031 (USD MILLION) 173
TABLE 138 NORTH AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 139 EUROPE: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY,
2024–2031 (USD MILLION) 174
TABLE 140 ASIA PACIFIC: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 141 LATIN AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 142 MIDDLE EAST: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION,
2024–2031 (USD MILLION) 175
TABLE 143 GCC COUNTRIES: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 144 EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION,
2024–2031 (USD MILLION) 176
TABLE 145 NORTH AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 146 EUROPE: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 147 ASIA PACIFIC: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 148 LATIN AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 149 MIDDLE EAST: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 150 GCC COUNTRIES: EPIGENETICS MARKET FOR CONVERSION ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 151 EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION,
2024–2031 (USD MILLION) 180
TABLE 152 NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 153 EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 154 ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 155 LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 156 MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,
BY REGION, 2024–2031 (USD MILLION) 182
TABLE 157 GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 158 EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION,
2024–2031 (USD MILLION) 183
TABLE 159 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 160 EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 161 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 162 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 163 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION,
2024–2031 (USD MILLION) 185
TABLE 164 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 165 EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION,
2024–2031 (USD MILLION) 186
TABLE 166 NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 167 EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 168 ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 169 LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 170 MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,
BY REGION, 2024–2031 (USD MILLION) 189
TABLE 171 GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 172 EPIGENETICS MARKET, BY SERVICE, 2024–2031 (USD MILLION) 191
TABLE 173 EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 192
TABLE 174 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 175 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 176 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 177 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 178 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 179 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 180 EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION,
2024–2031 (USD MILLION) 195
TABLE 181 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 182 EUROPE: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 183 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 184 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 185 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES,
BY REGION, 2024–2031 (USD MILLION) 198
TABLE 186 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 187 EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES,
BY REGION, 2024–2031 (USD MILLION) 199
TABLE 188 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 189 EUROPE: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 190 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 191 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 192 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 201
TABLE 193 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 194 EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION) 202
TABLE 195 NORTH AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 196 EUROPE: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 197 ASIA PACIFIC: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 198 LATIN AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 199 MIDDLE EAST: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION) 205
TABLE 200 GCC COUNTRIES: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 201 EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION,
2024–2031 (USD MILLION) 206
TABLE 202 NORTH AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 203 EUROPE: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 204 ASIA PACIFIC: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 205 LATIN AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 206 MIDDLE EAST: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION) 208
TABLE 207 GCC COUNTRIES: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 208 EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION,
2024–2031 (USD MILLION) 209
TABLE 209 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 210 EUROPE: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY,
2024–2031 (USD MILLION) 210
TABLE 211 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY,
2024–2031 (USD MILLION) 211
TABLE 212 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 213 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION,
2024–2031 (USD MILLION) 211
TABLE 214 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 215 EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 214
TABLE 216 EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 217 NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 218 EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 219 ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 220 LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 221 MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY REGION, 2024–2031 (USD MILLION) 217
TABLE 222 GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 223 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION) 219
TABLE 224 NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2024–2031 (USD MILLION) 219
TABLE 225 EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2024–2031 (USD MILLION) 220
TABLE 226 ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2024–2031 (USD MILLION) 220
TABLE 227 LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2024–2031 (USD MILLION) 221
TABLE 228 MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION,
2024–2031 (USD MILLION) 221
TABLE 229 GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2024–2031 (USD MILLION) 221
TABLE 230 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION,
2024–2031 (USD MILLION) 222
TABLE 231 NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 232 EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY,
2024–2031 (USD MILLION) 223
TABLE 233 ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 234 LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 235 MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION) 225
TABLE 236 GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 237 EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION) 226
TABLE 238 NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2024–2031 (USD MILLION) 226
TABLE 239 EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2024–2031 (USD MILLION) 227
TABLE 240 ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2024–2031 (USD MILLION) 227
TABLE 241 LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 242 MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION,
2024–2031 (USD MILLION) 228
TABLE 243 GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 244 EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2024–2031 (USD MILLION) 229
TABLE 245 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 246 EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 247 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 248 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 249 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 232
TABLE 250 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 251 EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 234
TABLE 252 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION,
2024–2031 (USD MILLION) 235
TABLE 253 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 254 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY,
2024–2031 (USD MILLION) 236
TABLE 255 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 256 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 257 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION,
2024–2031 (USD MILLION) 237
TABLE 258 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 259 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS 238
TABLE 260 EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION,
2024–2031 (USD MILLION) 239
TABLE 261 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION,
BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 262 EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 263 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATION,
BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 264 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION,
BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 265 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATION,
BY REGION, 2024–2031 (USD MILLION) 241
TABLE 266 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATION,
BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 267 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION,
2024–2031 (USD MILLION) 242
TABLE 268 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 269 EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,
2024–2031 (USD MILLION) 243
TABLE 270 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,
2024–2031 (USD MILLION) 243
TABLE 271 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 272 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER METHODS, BY REGION,
2024–2031 (USD MILLION) 244
TABLE 273 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 274 EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246
TABLE 275 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS 247
TABLE 276 EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 249
TABLE 277 NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 249
TABLE 278 EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 250
TABLE 279 ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 250
TABLE 280 LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 251
TABLE 281 MIDDLE EAST: EPIGENETICS MARKET FOR ONCOLOGY, BY REGION,
2024–2031 (USD MILLION) 251
TABLE 282 GCC COUNTRIES: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 251
TABLE 283 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION,
2024–2031 (USD MILLION) 252
TABLE 284 NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 285 EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY,
2024–2031 (USD MILLION) 253
TABLE 286 ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 287 LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 288 MIDDLE EAST: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION) 254
TABLE 289 GCC COUNTRIES: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 290 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION,
2024–2031 (USD MILLION) 256
TABLE 291 NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 256
TABLE 292 EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 257
TABLE 293 ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 257
TABLE 294 LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 295 MIDDLE EAST: EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION,
2024–2031 (USD MILLION) 258
TABLE 296 GCC COUNTRIES: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 297 EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,
2024–2031 (USD MILLION) 259
TABLE 298 NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 299 EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 300 ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 301 LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 302 MIDDLE EAST: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY REGION, 2024–2031 (USD MILLION) 261
TABLE 303 GCC COUNTRIES: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 304 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION,
2024–2031 (USD MILLION) 263
TABLE 305 NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 306 EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 307 ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 308 LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 309 MIDDLE EAST: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION) 265
TABLE 310 GCC COUNTRIES: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 311 EPIGENETICS MARKET FOR POPULATION SCREENING, BY REGION,
2024–2031 (USD MILLION) 266
TABLE 312 NORTH AMERICA: EPIGENETICS MARKET FOR POPULATION SCREENING,
BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 313 EUROPE: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 314 ASIA PACIFIC: EPIGENETICS MARKET FOR POPULATION SCREENING,
BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 315 LATIN AMERICA: EPIGENETICS MARKET FOR POPULATION SCREENING,
BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 316 MIDDLE EAST: EPIGENETICS MARKET FOR POPULATION SCREENING, BY REGION, 2024–2031 (USD MILLION) 269
TABLE 317 GCC COUNTRIES: EPIGENETICS MARKET FOR POPULATION SCREENING,
BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 318 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 270
TABLE 319 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 320 EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 271
TABLE 321 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 322 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 323 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 272
TABLE 324 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 325 EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 274
TABLE 326 EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2024–2031 (USD MILLION) 275
TABLE 327 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 328 EUROPE: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 329 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 330 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 331 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 277
TABLE 332 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 333 EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 278
TABLE 334 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 335 EUROPE: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 336 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 337 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 338 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 281
TABLE 339 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 340 EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION,
2024–2031 (USD MILLION) 282
TABLE 341 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 342 EUROPE: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 343 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 344 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 345 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2024–2031 (USD MILLION) 284
TABLE 346 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 347 EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2024–2031 (USD MILLION) 285
TABLE 348 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 349 EUROPE: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 350 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 351 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 352 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 287
TABLE 353 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 354 EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 290
TABLE 355 EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 291
TABLE 356 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 291
TABLE 357 EUROPE: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 358 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 359 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 360 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 293
TABLE 361 GCC COUNTRIES: EPIGENETICS SERVICE MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 362 EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2024–2031 (USD MILLION) 294
TABLE 363 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 364 EUROPE: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 365 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 366 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 367 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 296
TABLE 368 GCC COUNTRIES: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 297
TABLE 369 EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION,
2024–2031 (USD MILLION) 298
TABLE 370 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 298
TABLE 371 EUROPE: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 372 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 373 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 374 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2024–2031 (USD MILLION) 300
TABLE 375 GCC COUNTRIES: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 376 EPIGENETICS MARKET, BY REGION, 2024–2031 (USD MILLION) 302
TABLE 377 NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 303
TABLE 378 NORTH AMERICA: EPIGENETICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 304
TABLE 379 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 380 NORTH AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 305
TABLE 381 NORTH AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 305
TABLE 382 NORTH AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 306
TABLE 383 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 306
TABLE 384 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 307
TABLE 385 NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 307
TABLE 386 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 308
TABLE 387 NORTH AMERICA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 308
TABLE 388 US: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 309
TABLE 389 US: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 309
TABLE 390 US: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 310
TABLE 391 US: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 392 US: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 393 US: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 311
TABLE 394 US: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 312
TABLE 395 US: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 312
TABLE 396 US: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 313
TABLE 397 US: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 313
TABLE 398 CANADA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 314
TABLE 399 CANADA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 400 CANADA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 315
TABLE 401 CANADA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 402 CANADA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 403 CANADA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 316
TABLE 404 CANADA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 317
TABLE 405 CANADA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 317
TABLE 406 CANADA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 318
TABLE 407 CANADA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 318
TABLE 408 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 409 EUROPE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 319
TABLE 410 EUROPE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 411 EUROPE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 320
TABLE 412 EUROPE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 413 EUROPE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 414 EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 322
TABLE 415 EUROPE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 322
TABLE 416 EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 322
TABLE 417 EUROPE: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 323
TABLE 418 EUROPE: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 323
TABLE 419 GERMANY: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 324
TABLE 420 GERMANY: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 324
TABLE 421 GERMANY: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 325
TABLE 422 GERMANY: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 423 GERMANY: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 424 GERMANY: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 326
TABLE 425 GERMANY: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 327
TABLE 426 GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 327
TABLE 427 GERMANY: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 327
TABLE 428 GERMANY: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 328
TABLE 429 UK: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 328
TABLE 430 UK: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 431 UK: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 329
TABLE 432 UK: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 433 UK: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 434 UK: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 331
TABLE 435 UK: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 331
TABLE 436 UK: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 332
TABLE 437 UK: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 332
TABLE 438 UK: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 333
TABLE 439 FRANCE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 333
TABLE 440 FRANCE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 441 FRANCE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 334
TABLE 442 FRANCE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 443 FRANCE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 444 FRANCE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 336
TABLE 445 FRANCE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 336
TABLE 446 FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 337
TABLE 447 FRANCE: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 337
TABLE 448 FRANCE: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 338
TABLE 449 ITALY: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 338
TABLE 450 ITALY: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 451 ITALY: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 339
TABLE 452 ITALY: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 340
TABLE 453 ITALY: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 340
TABLE 454 ITALY: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 341
TABLE 455 ITALY: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 341
TABLE 456 ITALY: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 341
TABLE 457 ITALY: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 342
TABLE 458 ITALY: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 342
TABLE 459 SPAIN: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 343
TABLE 460 SPAIN: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 461 SPAIN: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 343
TABLE 462 SPAIN: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 463 SPAIN: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 464 SPAIN: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 345
TABLE 465 SPAIN: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 345
TABLE 466 SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 345
TABLE 467 SPAIN: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 346
TABLE 468 SPAIN: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 346
TABLE 469 REST OF EUROPE: EPIGENETICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 347
TABLE 470 REST OF EUROPE: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 347
TABLE 471 REST OF EUROPE: EPIGENETICS KITS & REAGENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 472 REST OF EUROPE: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 348
TABLE 473 REST OF EUROPE: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 349
TABLE 474 REST OF EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 349
TABLE 475 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 350
TABLE 476 REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 350
TABLE 477 REST OF EUROPE: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 350
TABLE 478 REST OF EUROPE: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 351
TABLE 479 ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 352
TABLE 480 ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 353
TABLE 481 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 353
TABLE 482 ASIA PACIFIC: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 353
TABLE 483 ASIA PACIFIC: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 484 ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 485 ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 355
TABLE 486 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 355
TABLE 487 ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 355
TABLE 488 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 356
TABLE 489 ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 356
TABLE 490 CHINA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 357
TABLE 491 CHINA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357
TABLE 492 CHINA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 357
TABLE 493 CHINA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 358
TABLE 494 CHINA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 358
TABLE 495 CHINA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 359
TABLE 496 CHINA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 359
TABLE 497 CHINA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 359
TABLE 498 CHINA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 360
TABLE 499 CHINA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 360
TABLE 500 JAPAN: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 361
TABLE 501 JAPAN: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 502 JAPAN: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 503 JAPAN: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 504 JAPAN: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 505 JAPAN: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 363
TABLE 506 JAPAN: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 364
TABLE 507 JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 364
TABLE 508 JAPAN: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 364
TABLE 509 JAPAN: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 365
TABLE 510 INDIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 365
TABLE 511 INDIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 366
TABLE 512 INDIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 366
TABLE 513 INDIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 514 INDIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 515 INDIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 368
TABLE 516 INDIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 368
TABLE 517 INDIA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 368
TABLE 518 INDIA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 369
TABLE 519 INDIA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 369
TABLE 520 AUSTRALIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 370
TABLE 521 AUSTRALIA: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 370
TABLE 522 AUSTRALIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 370
TABLE 523 AUSTRALIA: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 371
TABLE 524 AUSTRALIA: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 371
TABLE 525 AUSTRALIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 372
TABLE 526 AUSTRALIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 372
TABLE 527 AUSTRALIA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 372
TABLE 528 AUSTRALIA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 373
TABLE 529 AUSTRALIA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 373
TABLE 530 SOUTH KOREA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 374
TABLE 531 SOUTH KOREA: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 374
TABLE 532 SOUTH KOREA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 375
TABLE 533 SOUTH KOREA: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 375
TABLE 534 SOUTH KOREA: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 376
TABLE 535 SOUTH KOREA: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 376
TABLE 536 SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 377
TABLE 537 SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 377
TABLE 538 SOUTH KOREA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 377
TABLE 539 SOUTH KOREA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 378
TABLE 540 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 378
TABLE 541 REST OF ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 379
TABLE 542 REST OF ASIA PACIFIC: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 379
TABLE 543 REST OF ASIA PACIFIC: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 544 REST OF ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 545 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 381
TABLE 546 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 381
TABLE 547 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 382
TABLE 548 REST OF ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 382
TABLE 549 REST OF ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 383
TABLE 550 LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 383
TABLE 551 LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 384
TABLE 552 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 384
TABLE 553 LATIN AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 384
TABLE 554 LATIN AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 385
TABLE 555 LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 385
TABLE 556 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 386
TABLE 557 LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 386
TABLE 558 LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 386
TABLE 559 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 387
TABLE 560 LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 387
TABLE 561 BRAZIL: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 388
TABLE 562 BRAZIL: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 563 BRAZIL: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 389
TABLE 564 BRAZIL: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 565 BRAZIL: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 390
TABLE 566 BRAZIL: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 390
TABLE 567 BRAZIL: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 391
TABLE 568 BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 391
TABLE 569 BRAZIL: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 391
TABLE 570 BRAZIL: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 392
TABLE 571 MEXICO: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 392
TABLE 572 MEXICO: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393
TABLE 573 MEXICO: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 393
TABLE 574 MEXICO: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 575 MEXICO: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 576 MEXICO: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 395
TABLE 577 MEXICO: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 395
TABLE 578 MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 395
TABLE 579 MEXICO: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 396
TABLE 580 MEXICO: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 396
TABLE 581 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 397
TABLE 582 REST OF LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 583 REST OF LATIN AMERICA: EPIGENETICS KITS & REAGENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 584 REST OF LATIN AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 398
TABLE 585 REST OF LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 399
TABLE 586 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 399
TABLE 587 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 400
TABLE 588 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 400
TABLE 589 REST OF LATIN AMERICA: EPIGENETICS PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 401
TABLE 590 REST OF LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 401
TABLE 591 MIDDLE EAST: EPIGENETICS MARKET, BY REGION, 2024–2031 (USD MILLION) 402
TABLE 592 MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 402
TABLE 593 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 402
TABLE 594 MIDDLE EAST: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 595 MIDDLE EAST: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 596 MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 404
TABLE 597 MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 404
TABLE 598 MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 405
TABLE 599 MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 405
TABLE 600 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 405
TABLE 601 MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 406
TABLE 602 GCC COUNTRIES: EPIGENETICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 406
TABLE 603 GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 407
TABLE 604 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 407
TABLE 605 GCC COUNTRIES: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 407
TABLE 606 GCC COUNTRIES: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 408
TABLE 607 GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 408
TABLE 608 GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 409
TABLE 609 GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 409
TABLE 610 GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 409
TABLE 611 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 410
TABLE 612 GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 410
TABLE 613 SAUDI ARABIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 411
TABLE 614 SAUDI ARABIA: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 411
TABLE 615 SAUDI ARABIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 412
TABLE 616 SAUDI ARABIA: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 412
TABLE 617 SAUDI ARABIA: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 413
TABLE 618 SAUDI ARABIA: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 413
TABLE 619 SAUDI ARABIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 414
TABLE 620 SAUDI ARABIA: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 414
TABLE 621 SAUDI ARABIA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 414
TABLE 622 SAUDI ARABIA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 415
TABLE 623 UAE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 415
TABLE 624 UAE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 625 UAE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 416
TABLE 626 UAE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 627 UAE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 628 UAE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 418
TABLE 629 UAE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 418
TABLE 630 UAE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 418
TABLE 631 UAE: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 419
TABLE 632 UAE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 419
TABLE 633 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 420
TABLE 634 REST OF GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 420
TABLE 635 REST OF GCC COUNTRIES: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 636 REST OF GCC COUNTRIES: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 421
TABLE 637 REST OF GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 422
TABLE 638 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 422
TABLE 639 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 423
TABLE 640 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 423
TABLE 641 REST OF GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 424
TABLE 642 REST OF GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 424
TABLE 643 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 425
TABLE 644 REST OF MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 645 REST OF MIDDLE EAST: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 426
TABLE 646 REST OF MIDDLE EAST: EPIGENETICS ENZYMES MARKET, BY TYPE,
2024–2031 (USD MILLION) 426
TABLE 647 REST OF MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 427
TABLE 648 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 427
TABLE 649 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY METHOD,
2024–2031 (USD MILLION) 428
TABLE 650 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 428
TABLE 651 EST OF MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 429
TABLE 652 REST OF MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 429
TABLE 653 AFRICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 430
TABLE 654 AFRICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 430
TABLE 655 AFRICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 431
TABLE 656 AFRICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 657 AFRICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 432
TABLE 658 AFRICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 432
TABLE 659 AFRICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 433
TABLE 660 AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 433
TABLE 661 AFRICA: EPIGENETICS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 433
TABLE 662 AFRICA: EPIGENETICS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 434
TABLE 663 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
EPIGENETICS MARKET, JANUARY 2023–MAY 2026 435
TABLE 664 EPIGENETICS MARKET: DEGREE OF COMPETITION 439
TABLE 665 EPIGENETICS MARKET: REGION FOOTPRINT 444
TABLE 666 EPIGENETICS MARKET: PRODUCT FOOTPRINT 445
TABLE 667 EPIGENETICS MARKET: SERVICE FOOTPRINT 446
TABLE 668 EPIGENETICS MARKET: METHOD FOOTPRINT 447
TABLE 669 EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 450
TABLE 670 EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 451
TABLE 671 EPIGENETICS MARKET: PRODUCT/SERVICE LAUNCHES,
JANUARY 2023–MAY 2026 454
TABLE 672 EPIGENETICS MARKET: DEALS, JANUARY 2023–MAY 2026 455
TABLE 673 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 456
TABLE 674 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 457
TABLE 675 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,
JANUARY 2023–MAY 2026 460
TABLE 676 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–MAY 2026 460
TABLE 677 ILLUMINA, INC.: COMPANY OVERVIEW 462
TABLE 678 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 464
TABLE 679 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 466
TABLE 680 ILLUMINA, INC.: DEALS, JANUARY 2023–MAY 2026 467
TABLE 681 MERCK KGAA: COMPANY OVERVIEW 468
TABLE 682 MERCK KGAA: PRODUCTS/SERVICES OFFERED 469
TABLE 683 DANAHER CORPORATION: COMPANY OVERVIEW 472
TABLE 684 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 473
TABLE 685 DANAHER CORPORATION: DEALS, JANUARY 2023–MAY 2026 475
TABLE 686 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 476
TABLE 687 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 477
TABLE 688 REVVITY: COMPANY OVERVIEW 482
TABLE 689 REVVITY: PRODUCTS/SERVICES OFFERED 483
TABLE 690 PACBIO: COMPANY OVERVIEW 485
TABLE 691 PACBIO: PRODUCTS/SERVICES OFFERED 486
TABLE 692 PACBIO: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 487
TABLE 693 PACBIO: DEALS, JANUARY 2023–MAY 2026 488
TABLE 694 ACTIVE MOTIF, INC.: COMPANY OVERVIEW 489
TABLE 695 ACTIVE MOTIF, INC.: PRODUCTS/SERVICES OFFERED 489
TABLE 696 ACTIVE MOTIF, INC.: DEALS, JANUARY 2023–MAY 2026 492
TABLE 697 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 493
TABLE 698 NEW ENGLAND BIOLABS: PRODUCTS/SERVICES OFFERED 493
TABLE 699 NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 495
TABLE 700 NEW ENGLAND BIOLABS: DEALS, JANUARY 2023–MAY 2026 496
TABLE 701 QIAGEN: COMPANY OVERVIEW 497
TABLE 702 QIAGEN: PRODUCTS/SERVICES OFFERED 498
TABLE 703 QIAGEN: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 499
TABLE 704 ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW 500
TABLE 705 ZYMO RESEARCH CORPORATION: PRODUCTS/SERVICES OFFERED 500
TABLE 706 ZYMO RESEARCH CORPORATION: PRODUCT LAUNCHES,
JANUARY 2023–MAY 2026 503
TABLE 707 ZYMO RESEARCH CORPORATION: DEALS, JANUARY 2023–MAY 2026 503
TABLE 708 HOLOGIC DIAGENODE: COMPANY OVERVIEW 504
TABLE 709 HOLOGIC DIAGENODE: PRODUCTS/SERVICES OFFERED 505
TABLE 710 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 508
TABLE 711 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 509
TABLE 712 PROMEGA CORPORATION: COMPANY OVERVIEW 511
TABLE 713 PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED 511
TABLE 714 EPIGENTEK GROUP INC.: COMPANY OVERVIEW 513
TABLE 715 EPIGENTEK GROUP INC.: PRODUCTS/SERVICES OFFERED 513
TABLE 716 EPIGENTEK GROUP INC.: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 517
TABLE 717 EPICYPHER: COMPANY OVERVIEW 519
TABLE 718 FIOS GENOMICS: COMPANY OVERVIEW 520
TABLE 719 GENOMESCAN: COMPANY OVERVIEW 521
TABLE 720 CREATIVE BIOGENE: COMPANY OVERVIEW 522
TABLE 721 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW 523
TABLE 722 ABNOVA CORPORATION: COMPANY OVERVIEW 524
TABLE 723 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 525
TABLE 724 BIOMODAL: COMPANY OVERVIEW 526
TABLE 725 10X GENOMICS: COMPANY OVERVIEW 527
TABLE 726 NOVOGENE CO., LTD.: COMPANY OVERVIEW 528
TABLE 727 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 541
TABLE 728 RISK ASSESSMENT 543

LIST OF FIGURES

FIGURE 1 EPIGENETICS MARKET SEGMENTATION 47
FIGURE 2 EPIGENETICS MARKET: REGIONAL SCOPE 48
FIGURE 3 EPIGENETICS MARKET: YEARS CONSIDERED 49
FIGURE 4 MARKET SCENARIO 51
FIGURE 5 GLOBAL EPIGENETICS MARKET, 2024–2031 52
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET,
2023–2026 53
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF EPIGENETICS MARKET 54
FIGURE 8 HIGH-GROWTH SEGMENTS IN EPIGENETICS MARKET, 2026–2031 55
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN EPIGENETICS MARKET
DURING FORECAST PERIOD 56
FIGURE 10 GROWING EMPHASIS ON POPULATION SCREENING PROGRAMS TO DRIVE MARKET 57
FIGURE 11 DNA METHYLATION ACCOUNTED FOR LARGEST SHARE OF EPIGENETICS MARKET IN NORTH AMERICA IN 2025 58
FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH
DURING FORECAST PERIOD 59
FIGURE 13 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD 59
FIGURE 14 EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
FIGURE 15 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS 68
FIGURE 16 EPIGENETICS MARKET: VALUE CHAIN ANALYSIS 72
FIGURE 17 EPIGENETICS MARKET: ECOSYSTEM ANALYSIS 74
FIGURE 18 EPIGENETICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84
FIGURE 19 INVESTMENT AND FUNDING SCENARIO, 2023–2026 86
FIGURE 20 PATENT APPLICATIONS IN EPIGENETICS MARKET,
JANUARY 2015–DECEMBER 2025 96
FIGURE 21 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET 99
FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 113
FIGURE 23 KEY BUYING CRITERIA, BY END USER 114
FIGURE 24 EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (MILLION UNITS) 126
FIGURE 25 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT 303
FIGURE 26 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT 352
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN EPIGENETICS MARKET, 2021–2025 437
FIGURE 28 EPIGENETICS MARKET SHARE ANALYSIS, 2025 438
FIGURE 29 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 442
FIGURE 30 EPIGENETICS MARKET: COMPANY FOOTPRINT 443
FIGURE 31 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 449
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 452
FIGURE 33 EV/EBITDA OF KEY VENDORS 452
FIGURE 34 EPIGENETICS MARKET: BRAND COMPARATIVE ANALYSIS 453
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 457
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 463
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025) 469
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 473
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 477
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2025) 483
FIGURE 41 PACBIO: COMPANY SNAPSHOT (2025) 486
FIGURE 42 QIAGEN: COMPANY SNAPSHOT (2025) 498
FIGURE 43 HOLOGIC DIAGENODE: COMPANY SNAPSHOT (2025) 504
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 509
FIGURE 45 EPIGENETICS MARKET: RESEARCH DESIGN 529
FIGURE 46 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES 532
FIGURE 47 EPIGENETICS MARKET: INSIGHTS FROM PRIMARIES 533
FIGURE 48 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025 534
FIGURE 49 EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2025 535
FIGURE 50 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.:
REVENUE ANALYSIS (2025) 535
FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 537
FIGURE 52 EPIGENETICS MARKET: CAGR PROJECTIONS 539
FIGURE 53 EPIGENETICS MARKET: DATA TRIANGULATION 540

医療用ガスおよび機器市場規模、シェア、動向、2031年までの世界予測前の記事日本のアスレチックシューズ市場レポート　2026-2034年次の記事

Epigenetics Market - Global Forecast to 2031

調査範囲

本レポートを購入する主なメリット

本レポートでは、以下の点に関する知見を提供します

Report Description

Research Coverage

Key Benefits of Buying the Report

The report provides insights into the following pointers:

Table of Contents

LIST OF TABLES

LIST OF FIGURES

関連記事

幹細胞治療市場規模、シェア、動向、2035年までの世界予測

ヒトマイクロバイオーム市場 – 2031年までの世界予測

幹細胞と再生医療の世界市場